Please assess the completion status of the following clinical trial:

Trial Title: Tax First-line Chemotherapy With Different Doses and Then Maintenance Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria:~* Histologic or cytologic diagnosis of advanced non-small-cell lung cancer (NSCLC)~* Based on International Association for the Study of Lung Cancer (IASLC) 2009 new Tumor-Node-Metastasis (TNM) stage criteria of lung cancer, local advanced stage IIIB (not applicable for radical radiation therapy) disease or metastatic stage IV disease or recurrent disease~* At least one evaluable tumor lesion based on RECIST criteria (\>= 20 mm with conventional techniques or \>= 10 mm with spiral Computed Tomography scan)~* Eastern Cooperative Oncology Group performance status (ECOG PS) 0/1~* Adequate bone marrow reserve~  * absolute neutrophil count \>= 2.0×10\^9/L~ * platelets \>= 100×10\^9/L~ * hemoglobin \>= 9.0 g/dL~* Adequate hepatic function~  * total bilirubin \<= Upper Normal Limit (UNL)~ * Aspartate Amino Transferase (AST), Alanine Amino Transferase (ALT) \<= 2.5 UNL~ * alkaline phosphatase (ALP) \<= 5 UNL~* Adequate renal function (serum creatinine \<= UNL or creatinine clearance \>= 60 mL/min)~* No prior chemotherapy was allowed or only (neo) adjuvant chemotherapy ended more than 6 months before treatment (patients should not have been heavily pre-treated, the maximum cumulative dose of cisplatin allowed is 350 mg/m²)~* Prior surgery was permitted only if the operation performed more than 4 weeks ago and the patient was completely recovery~* Childbearing potential either terminated or attenuated by the use of an approved contraceptive method~* Inform consent signed~Exclusion criteria:~* Other tumour type than advanced / metastatic NSCLC in recent 5 years (except cone-biopsied carcinoma-in-situ of the cervix or adequately treated basal or squamous cell carcinoma of the skin).~* Presence of symptomatic central nervous system metastases~* Inadequate liver function~  * total bilirubin \> 1 UNL~ * ALT and/or AST\>1.5 UNL associated with alkaline phosphatase \> 2.5 UNL~ * inadequate renal function (creatinine \> 1.0 times UNL and in case of limit value, creatinine clearance \< 60 mL/min)~* Prior radiation therapy, or surgery operation within 4 weeks~* Prior use of taxoids~* Active infection, or serious concomitant systemic disorder incompatible with the study~* Childbearing potential but unwilling to use of an approved contraceptive method~* Receive treatment from other clinical trials during this study treatment~* History of hypersensitivity to any of study medication~* Other serious concomitant abnormal or illness~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- First line treatment: docetaxel 75 mg/m² + cisplatin 75 mg/m² (Type: EXPERIMENTAL): Docetaxel 75 mg/m² + cisplatin 75 mg/m² on day 1, repeated every 3 weeks, up to 4 cycles
- First line treatment:: docetaxel 60 mg/m² + cisplatin 75 mg/m² (Type: EXPERIMENTAL): Docetaxel 60 mg/m² + cisplatin 75 mg/m² on day 1, repeated every 3 weeks, up to 4 cycles
- Maintenance treatment: docetaxel (60 mg/m2) (Type: EXPERIMENTAL): Docetaxel 60 mg/m² on day 1, repeated every 3 weeks until progressive disease or up to 6 cycles
- Maintenance treatment: best supportive care (BSC) (Type: ACTIVE_COMPARATOR): BSC until progressive disease

Based on this trial design, predict the completion outcome and termination type (if applicable).